224 related articles for article (PubMed ID: 18160251)
1. [Chemotherapy for prostate cancer].
Medioni J; Dionysopoulos D; Banu E; Scotté F; Beuzeboc P; Oudard S
Presse Med; 2008 May; 37(5 Pt 2):814-20. PubMed ID: 18160251
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for chemotherapy in prostate cancer?
Canil CM; Tannock IF
Br J Cancer; 2004 Sep; 91(6):1005-11. PubMed ID: 15150548
[TBL] [Abstract][Full Text] [Related]
3. Update in the management of patients with hormone-refractory prostate cancer.
Moore CN; George DJ
Curr Opin Urol; 2005 May; 15(3):157-62. PubMed ID: 15815191
[TBL] [Abstract][Full Text] [Related]
4. Current chemotherapeutic approaches for androgen-independent prostate cancer.
Rumohr JA; Chang SS
Curr Opin Investig Drugs; 2006 Jun; 7(6):529-33. PubMed ID: 16784023
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
Oh WK
J Urol; 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. PubMed ID: 14610407
[TBL] [Abstract][Full Text] [Related]
6. Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Burgess EF; Roth BJ
Urol Clin North Am; 2006 May; 33(2):227-36, vii. PubMed ID: 16631461
[TBL] [Abstract][Full Text] [Related]
7. [Prostate cancer: future strategies for chemotherapy management].
Fizazi K
Ann Urol (Paris); 2007 Oct; 41 Suppl 3():S77-9. PubMed ID: 18297905
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy for prostate cancer.
Gilligan T; Kantoff PW
Urology; 2002 Sep; 60(3 Suppl 1):94-100; discussion 100. PubMed ID: 12231060
[TBL] [Abstract][Full Text] [Related]
9. Current indications for chemotherapy in prostate cancer patients.
Calabrò F; Sternberg CN
Eur Urol; 2007 Jan; 51(1):17-26. PubMed ID: 17007996
[TBL] [Abstract][Full Text] [Related]
10. Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
DeGrendele H
Clin Prostate Cancer; 2003 Mar; 1(4):212-4. PubMed ID: 15040878
[No Abstract] [Full Text] [Related]
11. The use of estramustine phosphate in the modern management of advanced prostate cancer.
Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.
Armstrong AJ; Carducci MA
Curr Oncol Rep; 2005 May; 7(3):220-7. PubMed ID: 15847714
[TBL] [Abstract][Full Text] [Related]
14. The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Eisenberger MA; Antonarakis ES
Urol Clin North Am; 2012 Nov; 39(4):573-81. PubMed ID: 23084532
[TBL] [Abstract][Full Text] [Related]
15. Cabazitaxel in prostate cancer: stretching a string.
Dorff TB; Quinn DI
Lancet; 2010 Oct; 376(9747):1119-20. PubMed ID: 20888974
[No Abstract] [Full Text] [Related]
16. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
Malhotra M; Dhingra R; Sharma T; Deep A; Narasimhan B; Phogat P; Sharma PC
Mini Rev Med Chem; 2013 May; 13(6):915-20. PubMed ID: 22950608
[TBL] [Abstract][Full Text] [Related]
18. [Prostate cancer and chemotherapy].
Gravis G; Salem N; Bladou F; Viens P
Bull Cancer; 2007 Jul; 94(7 Suppl):F21-8. PubMed ID: 17845990
[TBL] [Abstract][Full Text] [Related]
19. Treatment options in hormone-refractory prostate cancer: current and future approaches.
Harris KA; Reese DM
Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
[TBL] [Abstract][Full Text] [Related]
20. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
